SCIENTIFIC PROGRAMME
Thursday, April 2, 2020
09.00
Registration Opens
​
11.00 – 11.10
Welcome Address
​
11.10 – 11.30
TBA
​
11.30 – 13.00
Plenary Symposium 1: Emerging Concepts / New Agents
​
11.30 - 11.50
Myeloid immune checkpoint inhibition
​
11.50 - 12.10
Neoadjuvant in melanoma: a new model for testing new strategies for improving efficacy
​
12.10 - 12.30
CXCR3 required for anti-PD-1 efficacy
​
12.30 - 12.50
IL-15 for cancer therapy
​
12.50 - 13.10
T cell bispecific antibodies (4-1BB and tumor antigen)
​
13.10 – 14.00
Lunch
​
14.00 – 15.30
Plenary Symposium 2: Microbiome and immunotherapy
​
14.00 – 14.25
Microbiome and Immune System in Cancer
​
14.25- 14.40
Potential of fecal microbiota for early-stage detection of colorectal cancer
​
14.40-14.55
Crosstalk of the microbiome and epithelial cells
​
14.55 – 15.25
Microbiome and Immunotherapy in Cancer
​
15.25 – 15.40
Interplay of innate lymphoid cells and the microbiota
​
15:40- 15:55
The role of microbiota in GvHD and complications of allogeneic SCT
​
16.00 – 16.30
Coffee Break
​
16.30 – 18.40
Plenary Symposium 3: Tumor microenvironment
16.30 - 16.50
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
​
16.50 - 17.10
Immunoscore as possible predictive marker of response to treatments
​
17.10 - 17.30
Tumor intrinsic vs tumor extrinsic immune suppression
​
17.30 - 17.50
Multiplex in situ imaging and response to immunotherapy
​
17.50 - 18.10
Cancer cell shapes tumor microenvironment
​
18.10 - 18.25
TBA
18.25 - 18.40
TBA
18.40 – 22.00
Welcome Reception and Poster Viewing (at the venue)
Friday, April 3, 2020
08.30 – 09.30
Plenary Symposium 4: Vaccine Therapy
​
08.30 - 09.00
Preventative cancer vaccines and shared antigens
​
09.00 - 09.30
Multiple antigen-engineered DC vaccines promoting antitumor immunity in melanoma
​
09.30 – 10.30
Pro & Contra Sessions on Critical Topics
​
09.30 – 10.00
TBA
10.00 – 10.30
TBA
​
10.30 – 11.00
Coffee Break
​
11.00 – 12.30
Plenary Symposium 5: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)
​
11.00 – 11.30
High dimensional immune profiling in immunotherapy clinical trials
​
11.30 – 12.00
FcR macrophage and hyperprogressor
​
12.00 – 12.15
TBA
​
12.15 – 12.30
TBA
12.30 – 14.00
Lunch
​
14.00 – 15.00
Satellite Symposium (TBA)
15.00 – 15.45
Lifetime Achievement Award
​
15.45 – 16.15
Coffee Break
​
16.15 – 17.30
Plenary Symposium 6: “Lost in Translation”
​
16.15 – 16.45
TBA
​
16.45 – 17.15
TBA
​
17.15 – 17.30
TBA
​
17.30 – 18.30
Plenary Session 7: Young Researcher Session (from submitted abstracts)
​
17.30 – 17.45
TBA
​
17.45 – 18.00
TBA
​
18.00 – 18.15
TBA
18.15 – 18.30
TBA
​
19.30
ITOC7 Conference Dinner
​
​
Saturday, April 4, 2020
​
08.00 – 09.00
Plenary Symposium 8: Cell Therapy in Solid Tumors
​
08.00 – 08.15
Challenges of T-cell therapy in solid tumors
​
08.15 – 08.30
On the topic of novel CAR formats for solid tumors
​
08.30 – 08.45
Novel strategies to enable T cell therapy of cancer
​
08.45 – 09.00
CAR T cell therapy in non hematological pediatric cancer
​
09.00 – 10.30
Plenary Symposium 9: Cell Therapy in Haematologic Diseases
​
09.00 – 09.15
Cell therapy of hematological malignancies
​
09.15 – 09.30
CAR T cells for myeloma
​
09.30 – 09.45
Novel concepts for ALL cell therapy
​
09.45 – 10.00
TBA
​
10.30 – 11.00
Coffee Break
​
11.00 – 12.45
Plenary Symposium 10: Combination Therapy
​
11.00 – 11.15
Combination of immune modulation and check point blockade
​
11.15 - 11.30
Chemotherapy and antiPD-1 neoadjuvant Triple negative breast Cancer
​
11.30 - 11.45
IL-1 B inhibition and anti-PD-1
​
11.45 - 12.00
PD1 and targeting adenosine pathway
​
12.00 – 12.15
TBA
​
12.15 – 12.30
TBA
​
12.30 - 12.45
TBA
12.45 - 13.00
Best Poster Awards & Closing Remarks
13.00 – 14.00 Lunch